Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 3,285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progenitor Cells Clear all
Terminated Phase 2 Interventional Results available

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

NCT02272686
View directory record Official record
Conditions
Lymphoma
Interventions
Ibrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

NCT01746173
View directory record Official record
Conditions
T-cell Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 22, 2026, 5:14 PM EDT
Withdrawn Phase 1 Interventional

A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

NCT03097796
View directory record Official record
Conditions
Hematologic Diseases, Stem Cell Transplants
Interventions
PUL-042
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 22, 2026, 5:14 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Rejuvenation of Aged Muscle Stem Cells Through Exercise

NCT03473288
View directory record Official record
Conditions
Autophagy and Apoptosis in Human Satellite Cells
Interventions
Exercise, Sedentary
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 22, 2026, 5:14 PM EDT
Recruiting No phase listed Observational

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

NCT07636590
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
Non-interventional
Other
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Carmel, Indiana • Indianapolis, Indiana • Overland Park, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Not listed Phase 1 Interventional

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

NCT01711073
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Mobilization with G-CSF and Mozobil
Drug
Lead sponsor
Proteonomix, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Not applicable Interventional

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

NCT00038883
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Acute, Lymphoma, Low-Grade, Lymphoma, T-Cell, Lymphoma, B-Cell
Interventions
Campath-1H
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

NCT00604201
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA)
Interventions
Umbilical Cord Blood
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 22, 2026, 5:14 PM EDT
Completed No phase listed Observational

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

NCT02445612
View directory record Official record
Conditions
Stargardt's Macular Dystrophy
Interventions
MA09-hRPE
Biological
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

NCT05115630
View directory record Official record
Conditions
Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Cyclophosphamide, Mesna, Filgrastim, Melphalan, Fludarabine phosphate, Tacrolimus, Mycophenolate mofetil, Total Body Irradiation One Dose
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 22, 2026, 5:14 PM EDT
Not yet recruiting Phase 1 Interventional

Placental Cells for Diabetic Foot Ulcers

NCT07686094
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Placenta Stem Cells
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

NCT02161744
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ADSCs administration
Biological
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation

NCT05600101
View directory record Official record
Conditions
Hematopoietic Cell Transplantation
Interventions
Care.Coach
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 22, 2026, 5:14 PM EDT
Recruiting No phase listed Observational

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

NCT02677064
View directory record Official record
Conditions
Acute Leukemia, Newly Diagnosed, Relapsed
Interventions
assessments
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
1,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Hartford, Connecticut • New York, New York • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

NCT02880293
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
melphalan, fludarabine, thiotepa, Cyclophosphamide, Mesna, Mycophenolate Mofetil, Filgrastim, Tacrolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Not applicable Interventional

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

NCT02326675
View directory record Official record
Conditions
Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Interventions
Ice, Normal Saline Solution
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

NCT01596257
View directory record Official record
Conditions
Leukemia
Interventions
allogeneic hematopoietic stem cell transplantation, CliniMACS
Procedure · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 22, 2026, 5:14 PM EDT
Not listed Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

NCT00003163
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

NCT03699475
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
rivogenlecleucel, rimiducid, Cyclophosphamide, haplo-HSCT
Biological · Drug · Procedure
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
12 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

NCT01525407
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Atorvastatin Calcium, Peripheral Blood Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Stanford, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 22, 2026, 5:14 PM EDT
Not listed No phase listed Observational

Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation

NCT02990130
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Observational
Other
Lead sponsor
Garcia, Jose M., MD, PhD
Individual
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

NCT03600909
View directory record Official record
Conditions
Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions
Busulfan, Fludarabine, Cyclophosphamide, Anti-Thymocyte Globulin (Rabbit), The CliniMACS device, G-CSF
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
New York, New York • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 22, 2026, 5:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

NCT03403699
View directory record Official record
Conditions
Diabetes Complications, Diabetic Retinopathy
Interventions
Generation of inducible pluripotent stem cells
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 98 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 1Phase 2 Interventional

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

NCT00048399
View directory record Official record
Conditions
Graft Failure
Interventions
Fludarabine, CAMPATH 1H, FK506, Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 22, 2026, 5:14 PM EDT